New York State Common Retirement Fund Boosts Stake in Icon Plc $ICLR

New York State Common Retirement Fund raised its stake in shares of Icon Plc (NASDAQ:ICLR) by 180.1% during the third quarter, Holdings Channel.com reports. The institutional investor owned 224,785 shares of the medical research company’s stock after buying an additional 144,525 shares during the period. New York State Common Retirement Fund’s holdings in Icon were worth $39,337,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Tributary Capital Management LLC boosted its stake in shares of Icon by 84.5% during the third quarter. Tributary Capital Management LLC now owns 11,752 shares of the medical research company’s stock valued at $2,057,000 after acquiring an additional 5,381 shares during the last quarter. Stephens Investment Management Group LLC lifted its holdings in Icon by 15.7% in the 3rd quarter. Stephens Investment Management Group LLC now owns 480,104 shares of the medical research company’s stock valued at $84,018,000 after purchasing an additional 65,264 shares in the last quarter. Hudson Edge Investment Partners Inc. boosted its stake in shares of Icon by 12.4% during the 3rd quarter. Hudson Edge Investment Partners Inc. now owns 200,739 shares of the medical research company’s stock worth $35,129,000 after purchasing an additional 22,164 shares during the last quarter. SeaBridge Investment Advisors LLC purchased a new stake in shares of Icon during the third quarter worth about $2,589,000. Finally, Trinity Street Asset Management LLP raised its position in shares of Icon by 3.5% in the third quarter. Trinity Street Asset Management LLP now owns 870,973 shares of the medical research company’s stock valued at $152,420,000 after buying an additional 29,558 shares during the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Leerink Partners restated an “outperform” rating on shares of Icon in a research report on Monday, January 5th. Mizuho set a $216.00 price target on Icon in a research note on Friday, January 9th. Bank of America downgraded Icon from a “buy” rating to a “neutral” rating and set a $195.00 price objective for the company. in a research report on Monday, December 15th. BMO Capital Markets assumed coverage on Icon in a research note on Thursday, November 13th. They issued a “market perform” rating and a $175.00 target price for the company. Finally, Zacks Research raised Icon from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 25th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and eleven have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $200.60.

Icon Price Performance

Shares of Icon stock opened at $180.25 on Friday. The business’s fifty day moving average price is $183.96 and its 200 day moving average price is $176.40. Icon Plc has a twelve month low of $125.10 and a twelve month high of $211.00. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $14.56 billion, a P/E ratio of 24.39, a PEG ratio of 3.93 and a beta of 1.26.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.